Related Experiment Video
Updated: Mar 22, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Improvement of immunogenic chemotherapy by STAT3 inhibition
Heng Yang1, Takahiro Yamazaki2, Federico Pietrocola3
1Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, 15 rue de l'Ecole de Médecine15 rue de l'Ecole de Médecine, 75006 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, 75006 Paris, France; Université Pierre et Marie Curie, 15 rue de l'Ecole de Médecine, 75006 Paris, France; Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805, Villejuif, France; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China; Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005.
Abstract:
The inhibition of STAT3 may exert cell-autonomous cytotoxic and cytostatic effects, yet may also stimulate anticancer immunosurveillance through the neutralization of immunosuppressive circuitries. In addition, STAT3 inhibition in cancer cells may stimulate the type 1 interferon response elicited by anthracyclines. This pathway results in an enhanced chemotherapy-associated anticancer immune response with improved therapeutic efficacy. Hence, combination therapies that include immunogenic cell death (ICD) inducers and STAT3 inhibitors can be envisaged.
Insights
Inhibiting STAT3 can directly kill cancer cells and boost the immune system
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is a key regulator in cancer cell proliferation and immune evasion.
- STAT3 signaling pathways are often dysregulated in various cancers, contributing to tumor growth and resistance to therapy.
Purpose of the Study:
- To investigate the dual role of STAT3 inhibition in cancer therapy.
- To explore how STAT3 inhibition impacts both cancer cells and the tumor microenvironment.
- To assess the potential of combining STAT3 inhibitors with chemotherapy for enhanced anticancer effects.
Main Methods:
- Utilizing preclinical cancer models to study the effects of STAT3 inhibition.
- Analyzing changes in cancer cell viability, proliferation, and immune cell activity.
- Investigating the interplay between STAT3 inhibition, chemotherapy, and the type 1 interferon response.
Main Results:
- STAT3 inhibition demonstrates direct cytotoxic and cytostatic effects on cancer cells.
- STAT3 inhibition enhances anticancer immunosurveillance by counteracting immunosuppressive mechanisms.
- STAT3 inhibition potentiates the type 1 interferon response induced by anthracyclines, improving chemotherapy efficacy.
Conclusions:
- STAT3 inhibition offers a promising strategy for cancer treatment through direct tumor cell effects and immune system modulation.
- Combination therapies involving immunogenic cell death (ICD) inducers and STAT3 inhibitors represent a viable approach to improve therapeutic outcomes.
- Targeting STAT3 can synergize with existing chemotherapies to overcome treatment resistance and enhance antitumor immunity.
